Optimising the role of Herceptin® in breast cancer, proceedings of a symposium, Monte Carlo, June 19-21, 2000KHAYAT, David.Oncology. 2001, Vol 61, issn 0030-2414, 94 p., SUP2Conference Proceedings

New directions in anti-cancer chemotherapyKHAYAT, David.Seminars in oncology. 1995, Vol 22, Num 6, issn 0093-7754, 40 p., SUP14Serial Issue

Innovative Cancer Therapies: Putting Costs Into ContextKHAYAT, David.Cancer. 2012, Vol 118, Num 9, pp 2367-2371, issn 0008-543X, 5 p.Article

New approaches in cancer treatmentsKHAYAT, David.European journal of cancer. Supplement (1990). 2003, Vol 1, Num 2, issn 1359-6349, 71 p.Serial Issue

Comment organiser la lutte contre le cancer ?KHAYAT, David.RISQUES. 2005, Num 62, pp 8-15, issn 1152-9253, 8 p.Article

Cancer preventionKHAYAT, David.European journal of cancer. Supplement (1990). 2003, Vol 1, Num 1, issn 1359-6349, 43 p.Serial Issue

Thoracic MalignanciesKHAYAT, David.European journal of cancer. Supplement (1990). 2004, Vol 2, Num 4, issn 1359-6349, 45 p.Conference Proceedings

New Directions in Anticancer Chemotherapy. SymposiumKHAYAT, David.Seminars in oncology. 1997, Vol 24, Num 4, issn 0093-7754, 40 p., SUP11Conference Proceedings

Carboplatin : present status and future directions. SymposiumKHAYAT, David.Oncology. 1993, Vol 50, issn 0030-2414, SUP2Conference Proceedings

New perspectives in the management of non-small cell lung cancer (NSCLC): Gefitinib (Iressa, ZD 1839)MANEGOLD, C.European journal of cancer. Supplement (1990). 2004, Vol 2, Num 4, pp 34-39, issn 1359-6349, 6 p.Conference Paper

Antisense therapy for cancerCOTTER, F. E.European journal of cancer. Supplement (1990). 2003, Vol 1, Num 2, pp 19-27, issn 1359-6349, 9 p.Article

Herceptin® alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: Pivotal trialsBASELGA, José.Oncology. 2001, Vol 61, pp 14-21, issn 0030-2414, SUP2Conference Paper

Dose scheduling - Herceptin®LEYLAND-JONES, Brian.Oncology. 2001, Vol 61, pp 31-36, issn 0030-2414, SUP2Conference Paper

Testing for HER2 statusHANNA, Wedad.Oncology. 2001, Vol 61, pp 22-30, issn 0030-2414, SUP2Conference Paper

Current status and future directions of platinum/paclitaxel-based chemotherapy of ovarian cancerMARKMAN, M.Seminars in oncology. 1997, Vol 24, Num 4, pp S11-24, issn 0093-7754, -S11-27, SUP11Conference Paper

High-dose carboplatin in the treatment of hematologic malignanciesVOGLER, W. R.Oncology. 1993, Vol 50, pp 42-46, issn 0030-2414, SUP2Conference Paper

Management of small cell lung cancerTHATCHER, N.European journal of cancer. Supplement (1990). 2004, Vol 2, Num 4, pp 40-43, issn 1359-6349, 4 p.Conference Paper

The role of imaging in screening, diagnosis and staging of non-small cell lung cancer (NSCLC)RANKIN, S. C.European journal of cancer. Supplement (1990). 2004, Vol 2, Num 4, pp 7-14, issn 1359-6349, 8 p.Conference Paper

Angiogenesis as a new target for cancer controlHARRIS, A. L.European journal of cancer. Supplement (1990). 2003, Vol 1, Num 2, pp 1-12, issn 1359-6349, 12 p.Article

Conceptual basis for advances in the systemic drug therapy of breast cancerNORTON, L.Seminars in oncology. 1997, Vol 24, Num 4, pp S11-2, issn 0093-7754, -S11-12, SUP11Conference Paper

Single-agent paclitaxel at first relapse following adjuvant chemotherapy for breast cancerDAVIDSON, N. G.Seminars in oncology. 1995, Vol 22, Num 6, pp 2-6, issn 0093-7754, SUP14Article

Progress in ovarian cancer: an overview and perspectiveOZOLS, R. F.European journal of cancer. Supplement (1990). 2003, Vol 1, Num 2, pp 43-55, issn 1359-6349, 13 p.Article

Biology of HER2 and its importance in breast cancerYARDEN, Yosef.Oncology. 2001, Vol 61, pp 1-13, issn 0030-2414, SUP2Conference Paper

Changer la prise en charge du cancerKHAYAT, David; WELTY, Christine.Actualité et dossier en santé publique. 2005, Num 51, issn 1243-275X, 1Article

Page / 5